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Indacaterol is a novel, inhaled, long-acting b2-agonist providing 24-h bronchodilation with
once-daily (o.d.) dosing in patients with COPD.
In this double-blind, incomplete block crossover study, patients with moderate-to-severe
COPD were randomised to receive three treatment cycles from: indacaterol 300 mg o.d. dosed
PM or AM, salmeterol 50 mg twice daily or placebo, each for 14 days. Trough FEV1 was measured
24 h after indacaterol, and 12 h after salmeterol.
Ninety-six patients (mean age: 64 years; post-bronchodilator FEV1 57% predicted, FEV1/FVC
55%) were randomised; 83 completed. After 14 days, the difference vs. placebo in trough FEV1
for PM indacaterol was 200 mL (p < 0.001 [primary analysis]) and for AM indacaterol was
200 mL (p < 0.001). Compared with salmeterol, trough FEV1 for PM indacaterol was 110 mL
higher (p < 0.001), and for AM indacaterol was 50 mL higher (p Z NS). Over 14 days, vs.
placebo, both PM and AM indacaterol improved the % of nights with no awakenings (by 11.9
and 8.1 points; p < 0.01); the % of days with no daytime symptoms (by 6.7 and 5.5 points;
p < 0.05); and the % of days able to perform usual activities (by 6.7 and 7.8 points; p < 0.05).
Indacaterol provided 24-h bronchodilation and improvement in symptoms regardless of
whether taken regularly in the morning or evening.
Clinical trial registration: ClinicalTrials.gov NCT00615030.
ª 2010 Elsevier Ltd. All rights reserved.778 9479; fax: þ1 973 781 8265.
novartis.com (B. Kramer).
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Chronic obstructive pulmonary disease (COPD) is associated
with rising morbidity and mortality, and is predicted to
become the third leading cause of death worldwide by
2030.1 Other co-morbid conditions are common (including
cardiovascular)2,3 these may not only impact the general
health of COPD patients, but also disease management.
With these challenges, pharmacologic intervention that
offers ease of drug administration together with minimal
side effects is of key concern in the effective management
of COPD. Treatment guidelines, such as those from the
Global Initiative for Chronic Obstructive Lung Disease
(GOLD),4 describe the use of bronchodilators including
inhaled b2-agonists as central to the symptomatic
management of COPD, and regular treatment with long-
acting bronchodilators (including long-acting b2-agonists
[LABAs]) as more effective and convenient than short-
acting bronchodilators.
Indacaterol is a novel, inhaled once-daily (o.d.) LABA,
that (at the time of preparation of this manuscript e August
2010) is approved in the European Union (EU) for the
treatment of COPD. The recommended dose of indacaterol
in the EU is 150 mg o.d.; the 300 mg dose has been shown to
provide additional clinical benefit with regard to breath-
lessness, particularly for patients with severe COPD. In
previous studies, the 24-h efficacy of indacaterol has been
demonstrated following morning dosing. However, some
patients e perhaps influenced by their lifestyles e may
prefer a different dosing time. Further, in some cases
clinicians may wish to recommend evening dosing, for
example if a patient experiences nocturnal symptoms. It
was therefore important to demonstrate, as part of its
clinical development, that the efficacy of indacaterol was
unaffected by dosing time. Consequently, this study was
designed to compare the efficacy of indacaterol 300 mg
dosed o.d. in the evening with that of placebo (primary
efficacy variable). The study included two active compar-
ators, indacaterol 300 mg dosed o.d. in the morning, and
salmeterol 50 mg twice daily (b.i.d.).
Methods
This was a randomised, double-blind, double-dummy,
placebo-controlled, incomplete block crossover study. It
was conducted in accordance with the Declaration of Hel-
sinki (1989), ICH Good Clinical Practice, and local appli-
cable laws and regulations. Institutional review board or
ethics committee approval was obtained for each partici-
pating study centre. All patients provided written informed
consent prior to participating in the study.
Study population
The study population included male and female patients
40 years of age with moderate-to-severe COPD. Patients
were to have a post-bronchodilator forced expiratory
volume in 1 s (FEV1) <80% and 30% of the predicted
normal value, post-bronchodilator FEV1/forced vital
capacity (FVC) < 70% and a history of smoking of at least 20pack years. Factors preventing entry to the study included
recent respiratory tract infection or hospitalisation for
COPD exacerbation, significant concomitant pulmonary
disease, history of asthma, Type I or uncontrolled Type II
diabetes, or any condition that might have compromised
patient safety or compliance. Patients were also excluded
if they had irregular day/night, waking/sleeping cycles
(e.g., night shift workers).
Study design
The study included a pre-screening visit followed by a 14-day
run-in period. During the pre-screening visit, patients were
assessed for study eligibility, informed consent was
obtained, and patients were transferred from prohibited to
allowable COPD therapy. In the run-in period, the eligibility
of patients was confirmed and baseline diary data were
obtained. Eligible patients were then randomly allocated to
one of 12 treatment sequences, each comprising three
double-blind, 14-day treatment periods, with treatment
periods separated by 14-day washout periods. In each
treatment sequence, patients received three of the
following four possible blinded treatments: indacaterol
300 mg o.d. administered in the evening (PM indacaterol) via
a single-dose dry powder inhaler (SDDPI), indacaterol 300 mg
o.d. administered in the morning (AM indacaterol) via
SDDPI, salmeterol 50 mg b.i.d. via multi-dose dry powder
inhaler, and placebo. Throughout the treatment periods,
patients used both devices twice daily tomaintain the blind.
Patients were permitted to use inhaled corticosteroids at
a dose and regimen to remain stable throughout the study,
but only if they had had that regimen for one month prior to
screening.
Efficacy assessments
On Day 1 of each treatment period, spirometry was per-
formed at 50 and 15 min pre-dose, and at 5, 15, and 30 min,
and 1 h post-dose in the morning and evening. In the
evening of Day 14 of each period, spirometry was per-
formed at 15 min pre-dose. In the morning and evening of
Day 15, spirometry was performed at 23 h 10 min and 23 h
45 min post-dose, based on the time of morning and
evening dosing on the previous day. Trough FEV1 was
calculated using data from assessments approximately 24 h
after the two indacaterol Day 14 doses (i.e., in the morning
of Day 15 for the AM regimen and the evening of Day 15 for
the PM regimen), 12 h after each Day 14 salmeterol dose
(i.e., in the evening of Day 14 and the morning of Day 15),
and 24 h after each Day 14 placebo dose (i.e., in the
morning and evening of Day 15), as illustrated in Fig. 1.
Outcomes
The primary efficacy variable was assessed by comparing
the 24-h post-dose (trough) FEV1 (mean of the FEV1
measurements at 23 h 10 min and 23 h 45 min post-dose) of
PM indacaterol with that of placebo after 14 days of
treatment (‘evening trough’). In addition, the difference in
‘morning trough’ FEV1 post Day 14 dose between AM
Figure 1 Trough FEV1 assessments versus study drug dosing time. FEV1: forced expiratory volume in 1 s; *: For salmeterol, this is
equivalent to the mean of FEV1 at 11 h 10 min and 11 h 45 min following Day 14 evening dose.
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ence between PM indacaterol and AM indacaterol. The
trough FEV1 values for salmeterol (after morning and
evening doses on Day 14) were also compared with inda-
caterol and placebo.
Other outcomes included assessment of FEV1 at indi-
vidual time points on Day 1 of each treatment period, and
trough FVC measured after 14 days of treatment. Patients
completed diaries twice daily to record the presence of
symptoms; symptom scores were assessed at the end
of each 2-week treatment period, to determine the
percentage of nights with no night-time awakenings, the
percentage of days with no daytime symptoms, and
the percentage of days a patient was able to perform usual
daily activities.
All adverse events (AEs) and serious AEs (SAEs) were
evaluated in terms of severity, duration, and relationship to
study drug. Safety was also assessed in terms of regular
assessments of haematology, blood chemistry (including
serum potassium and blood glucose), urine analysis, vital
signs, and electrocardiogram data, with physical examina-
tions conducted at the beginning and end of study.
The systemic exposure of indacaterol was determined by
assessing the serum concentration of indacaterol in the
morning and the evening at 30 min post-dose on Day 14 of
each treatment period. A total volume of 3 mL of blood was
drawn into a plain glass tube, left to clot at room
temperature for 20 min, before being centrifuged for
10 min at approximately 2500 g. The resultant serum wasassayed by liquid chromatography/tandem mass spec-
trometry, with a lower limit of quantification (LLOQ) of
10.0 pg/mL (expressed as base) using 200 mL of serum, with
values below the LLOQ treated as zero. Serum levels were
only included in data analysis when actual sampling time
was recorded. The mean (standard deviation [SD]) serum
concentration of indacaterol was compared between the
morning and evening doses.
Sample size and statistical analysis
Assuming a standard deviation of 230 mL, as observed in
previous indacaterol and formoterol studies, inflated by
10% to adjust for diurnal variation, 62 evaluable patients
were required to detect a difference in trough FEV1 of
120 mL between indacaterol 300 mg and placebo with 5%
significance level (two-sided) and 90% power. Allowing
a drop-out rate of 20%, a minimum sample size of 78
patients was chosen to provide 90% power for analysis of
the primary endpoint.
Efficacy variables were analysed using data from the
modified intention-to-treat (mITT) population, which
included all randomised patients who received at least one
dose of study drug. All safety analyses were performed on
the safety population, which included all subjects who
received at least one dose of the study medication.
The primary variable was analysed using an analysis of
covariance (ANCOVA) model with patient as random effect,
and period baseline FEV1 (mean of values measured at 50
1872 H. Magnussen et al.and 15 min prior to the first study drug administration on
the morning of Day 1 in that period), period, treatment
group, daytime (time of the day at which the FEV1
measurements were taken: am, pm), and treatment by
daytime interaction as fixed effects. All secondary efficacy
analyses were performed on the mITT population using
a similar ANCOVA model. Adjusted treatment differences
were estimated along with the associated 95% confidence
interval and two-sided p-values. Trough FVC data are pre-
sented as summary statistics only (change from baseline);
confidence intervals were not calculated.
Results
This study was conducted at 13 centres in 3 countries
(Germany, Spain, and France). The first patient was
enrolled on January 22, 2008; the last patient completed on
July 29, 2008.
Patient disposition, demographics, and baseline
characteristics
A total of 125 patients were screened, with 96 randomised
to the 12 treatment sequences, and 83 (86.5%) completing
(Fig. 2). One patient, who did not receive study drug due to
abnormal test procedure results, was excluded from the
mITT and safety populations. All patients included in theFigure 2 Patient disposition mmITT population were also included in the safety pop-
ulation (n Z 95). All patients were Caucasian, with the
majority male and a mean age of 64 years (Table 1). There
was a wide range in duration of COPD, from newly-diag-
nosed patients up to 29.8 years.
Efficacy
For the primary efficacy endpoint, trough FEV1 on Day 15,
PM indacaterol 300 mg was superior to placebo (p < 0.001)
with a difference of 200 mL, exceeding the pre-specified
minimum clinically important difference of 120 mL (Fig. 3).
The treatmenteplacebo difference in trough FEV1 for AM
indacaterol was also 200 mL (p < 0.001), with a difference
between PM indacaterol and AM indacaterol of 10 mL
(p Z NS). There was a statistically significant difference in
trough FEV1 between PM indacaterol and salmeterol pm
(p < 0.001). Although AM indacaterol was associated with
a higher trough FEV1 than salmeterol am, this difference
did not reach statistical significance. The least squares
mean values for trough FEV1 after 14 days were 1.57, 1.56,
1.37, 1.36, 1.46, and 1.51 L for PM indacaterol, AM inda-
caterol, placebo pm, placebo am, salmeterol pm, and sal-
meterol am, respectively (all with standard errors of
0.025L).
For individual time point FEV1 values on Day 1, all active
treatments were statistically superior to placebo at all post-ITT: modified intent to treat.
Table 1 Demographic andbaseline clinical characteristics.
Total N Z 95
Age (years), mean (SD) 64.1 (8.70)
Age group, n (%)
40e64 years 53 (55.8)
65 years 42 (44.2)
Sex, n (%)
Male 80 (84.2)
Female 15 (15.8)
Race, n (%): Caucasian 95 (100)
BMI (kg/m2), mean (SD) 26.9 (4.52)
Duration of COPD (years),
mean (SD)
8.9 (6.21)
Smoking history, n (%)
Ex-smoker 53 (55.8)
Smoker 42 (44.2)
Estimated number of pack
years, mean (SD)
47.3 (20.14)
FEV1 (L), mean (SD)
a 1.6 (0.44)
FEV1 (% predicted), mean (SD)
a 56.6 (13.68)
FEV1/FVC (%), mean (SD)
a 54.9 (8.34)
FEV1 reversibility (%),
mean (SD)a
12.6 (16.07)
SD: standard deviation; BMI: body mass index (weight in kilo-
gram/height in square metres); FEV1: forced expiratory volume
in 1 s.
a Post-salbutamol.
Figure 3 Estimated treatment differences and associated 95% co
in mITT population Data presented are least squares mean treat
interval; FEV1: forced expiratory volume in 1 s; **: p < 0.01; ***:
morning dose on Day 14; Pbo: placebo; PM Ind: trough FEV1 assess
trough FEV1 assessed 12 h after salmeterol evening dose on Day 14;
dose on Day 14.
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indacaterol as this was prior to administration of study drug).
At 5 min post-first dose, the treatmenteplacebo difference
in FEV1 for AM indacaterol was 150 mL, and for PM indaca-
terol was 140 mL (both p < 0.001 vs. placebo). The FEV1 for
both indacaterol regimens was numerically higher than that
of salmeterol at all post-exposure time points, with statis-
tical significance observed between AM indacaterol and
salmeterol at all time points on Day 1 until the second sal-
meterol dose was taken.
Mean changes from baseline FEV1 assessed in the
evening of Day 14 (at 11 h 45 min after the time of morning
dosing) and the morning of Day 15 (at 11 h 45 min after the
time of Day 14 evening dosing) are shown in Fig. 5. Both
indacaterol regimens provided similar bronchodilator effi-
cacy, with changes from baseline that were higher than
those with salmeterol or placebo.
Similar results were observed for trough FVC after 14
days dosing. In the analysis of evening trough FVC, the
mean change from baseline for PM indacaterol was 220 mL,
compared with 110 mL for salmeterol pm and 0 mL for
placebo. For morning trough FVC, the mean change from
baseline for AM indacaterol was 240 mL, compared with
170 mL for salmeterol am and 0 mL for placebo.
Over 14 days of treatment, compared with placebo, both
indacaterol regimens significantly improved the percentage
of nights with no awakenings, the percentage of days with
no daytime symptoms, and the percentage of days able to
perform usual activities (Table 2). Improvements in all of
these analyses were consistently in favour of indacaterol
(both regimens) over salmeterol, with the difference
reaching statistical significance for PM indacaterol in thenfidence intervals of trough FEV1 (L) after 14 days of treatment
ment difference and 95% confidence interval. CI: confidence
p < 0.001; AM Ind: trough FEV1 assessed 24 h after indacaterol
ed 24 h after indacaterol evening dose on Day 14; Salm (am):
Salm (pm): trough FEV1 assessed 12 h after salmeterol morning
Figure 4 Least squares means of FEV1 (L) post-period baseline on Day 1 in mITT population Data presented are least squares
means  standard error. yy: p < 0.01, yyy: p < 0.001 vs. salmeterol. Treatment differences versus placebo were significant for
indacaterol (p < 0.001) and salmeterol (p < 0.01) at each post-dose time point.
1874 H. Magnussen et al.analysis of percentage of nights with no awakenings. There
were no significant differences between the two indaca-
terol regimens.
Safety
The overall incidence of AEs was comparable between
treatments (23.1, 25.0, 19.1, and 20.6% with indacaterol
PM, indacaterol AM, salmeterol, and placebo, respec-
tively); most AEs were mild or moderate in severity. Cough
was the most frequently reported suspected drug-relatedFigure 5 Mean difference from baseline in absolute FEV1 (L)
on Days 14 and 15 in mITT population Data presented are the
mean (unadjusted) differences from baseline in absolute FEV1
(L). The Day 14 evening timepoint is 15 min before the time of
evening dosing (equivalent to 11 h 45 min after Day 14 morning
dosing). The Day 15 morning timepoint is 11 h 45 min after the
time of Day 14 evening dosing (equivalent to 23 h 45 min after
Day 14 morning dosing). FEV1: forced expiratory volume in 1 s.AE with indacaterol treatment in this study (7.7 and 5.9%
with PM and AM indacaterol, compared with 1.5% with
salmeterol and 0% with placebo); all events were mild or
moderate in intensity and transient in nature, and none
resulted in treatment discontinuation. SAEs were reported
in two patients e one of rib fracture during AM indacaterol
treatment and another of lung cancer with brain metastasis
reported during the follow-up period of PM indacaterol
treatment; neither was suspected to be study drug-related.
No death was reported during the study.
Class-related side effects of b2-agonists include hypo-
kalaemia, hyperglycaemia, increased pulse rate, and QTc
interval prolongation. No notably low potassium values
were reported in the study, and the incidence of notably
high glucose levels was similar for all treatments, including
placebo. No major effects on pulse rate or blood pressure
were observed. One patient experienced QTc interval
(Fridericia’s) values >500 ms in both AM indacaterol and
salmeterol treatment periods; these values were not the
result of notable increases from baseline, and although the
patient discontinued from the study due to an AE (anaemia,
considered mild and not related to study medication), the
high QTc interval values were not suspected related to
study medication. The only increase in QTc interval from
baseline >60 ms was in the placebo treatment group; the
increase was not to a notable value.
Pharmacokinetics
A total of 112 samples were analysed for serum
indacaterol levels, 57 from patients receiving AM indaca-
terol and 55 from patients receiving PM indacaterol. Four
of these samples (3.6%) had indacaterol concentrations
below LLOQ (three with AM indacaterol and one with PM
indacaterol). The actual sampling times post-dose in the
AM and PM groups compared well (mean  SD of 0.55  0.07
Table 2 Treatment contrasts of symptom scores (LSM  SEM) over 14 days of treatment.
Percent of nights
with no night-time
awakenings
Percent of days
with no daytime
symptoms
Percent of days
able to perform
usual daily activities
PM indacaterol 300 mg vs. placebo 11.9  3.08*** 6.7  2.59* 6.7  3.30*
AM indacaterol 300 mg vs. placebo 8.1  3.07** 5.5  2.58* 7.8  3.29*
Salmeterol vs. placebo 5.4  3.05 4.2  2.57 3.5  3.27
PM indacaterol 300 mg vs. salmeterol 6.5  3.09* 2.5  2.60 3.1  3.33
AM indacaterol 300 mg vs. salmeterol 2.7  3.08 1.3  2.59 4.3  3.30
PM indacaterol 300 mg vs. AM indacaterol 300 mg 3.8  3.12 1.2  2.61 1.2  3.34
LSM: least squares mean; SEM: standard error of the mean.
***p < 0.001; **p < 0.01; *p < 0.05.
24-h efficacy of indacaterol dosed AM or PM 1875and 0.53  0.08 h post-dose, respectively) allowing
direct comparison of the serum levels between the two
groups. The mean  SD serum concentration of indacaterol
30 min after AM indacaterol dosing on Day 14 was
465.2  247.3 pg/mL, compared with 463.3  246.1 pg/mL
30 min after PM indacaterol dosing.
Discussion
In this study, the clinically relevant treatmenteplacebo
difference observed with indacaterol dosed in the evening
(200 mL) was the same as that seen with indacaterol dosed
in the morning. This treatmenteplacebo difference was
well in excess of the value pre-specified as clinically
significant (120 mL), as were the treatmenteplacebo
differences at all post-exposure time points on Day 1.
Furthermore, both indacaterol regimens were associated
with an onset of action within 5 min of the first dose, and
the two regimens resulted in similar changes from baseline
in FEV1 and in trough FVC after 14 days of dosing. One may
conclude from this that the 24-h duration of bronchodilator
efficacy of indacaterol is unaffected by the time of day at
which the patients took their medication. Further, although
there is some evidence of diurnal variation in the efficacy
of indacaterol and salmeterol (as can be seen in the change
from baseline data for FEV1 on Days 14 and 15), after 14
days of dosing the two regimens of indacaterol provided
consistent bronchodilator efficacy. For example, in the
morning assessment on Day 15, the change from baseline
FEV1 data assessed approximately 12 h after indacaterol
dosed in the evening was the same as that assessed
approximately 24 h after indacaterol dosed in the morning.
In terms of the patient diary data, both indacaterol
regimens provided statistically significant improvements in
all endpoints compared with placebo. However, evening
dosing of indacaterol was associated with a numerically
greater improvement in nocturnal symptoms than morning
dosing, reaching statistical significance compared with
salmeterol. This suggests that it may be possible to
personalise a regimen to the needs of an individual patient.
The 14-day treatment period was selected for this study
as previous studies have shown that indacaterol reaches
pharmacodynamic steady-state prior to this time5,6 simi-
larly in an earlier study the bronchodilator efficacy of sal-
meterol after 14 days of treatment was comparable to that
seen after 1 year.7 The efficacy of both indacaterol regi-
mens in this study was consistently numerically greaterthan that of salmeterol twice daily e even at time points on
the evening of Day 1 just after the second salmeterol dose
had been taken, that were the equivalent of mid-way
through the AM indacaterol dose interval. Similar results
have been observed in two other studies comparing inda-
caterol and salmeterol e one of 26 weeks duration,8 and
the other a 14-day crossover design.9 Of note, in the longer
duration study there was no loss in bronchodilator efficacy
with indacaterol on o.d. dosing for 26 weeks.8
Currently the only o.d. inhaled bronchodilator available
is the long-acting muscarinic antagonist tiotropium. During
its clinical development, the effect of tiotropium on
the circadian variation of airway calibre was assessed, in
a study comparing morning or evening dosing of tiotropium
with placebo.10 The bronchodilator results of the two tio-
tropium regimens were broadly comparable, with steady-
state tiotropiumeplacebo differences in FEV1 of 210 and
160 mL for the AM and PM regimens, respectively. Further,
the investigators observed a circadian variation in lung
function, with FEV1 at its lowest in the early hours of the
morning e perhaps helping to explain why patients are
most likely to experience symptoms of their disease in the
morning.10 Although no studies have compared evening
dosing of indacaterol with evening dosing of tiotropium,
a number have compared morning dosing of the two bron-
chodilators. In one, for the primary endpoint (12 weeks) the
trough FEV1 for indacaterol 300 mg was 40 mL higher than
that of open-label tiotropium (p Z 0.01).11 In a second
study, the trough FEV1 for indacaterol 300 mg was 30 mL
higher than that of blinded tiotropium (p Z NS).12
Both indacaterol regimens were well tolerated with
a good overall safety profile and a low discontinuation rate.
No notable differences were reported between the two
active treatments and placebo in pulse rate, blood pressure,
orQTc interval. In addition, the serum levels of indacaterol at
30 min post-inhalation were similar between the AM and PM
treatments, indicating that systemic exposure is indepen-
dent of the dosing time. This safety profile is consistent with
that observed in previous studies, including a single-dose
study with supratherapeutic doses up to 3000 mg,13 and
a study up to 52 weeks with doses of 300 mg or 600 mg o.d.14
Conclusion
These results have been obtained in a group of patients
with moderate-to-severe COPD who would be suitable
candidates for long-acting bronchodilator therapy. This
1876 H. Magnussen et al.study, by confirming that indacaterol provides 24-h bron-
chodilator efficacy in both regimens, indicates that
patients may be given the option of choosing a dosing time.
Moreover the results suggest that once-daily indacaterol
may be more effective than salmeterol dosed twice daily.
The combination of once-daily dosing with choice of dosing
time and fast onset of action may in turn help to enhance
compliance.
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